SNTI on Nasdaq
Senti Biosciences Holdings, Inc.
In its 2026 annual report the company says: “We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. We are applying our gene circuit technologies to develop a pipeline of medicines that use chimeric antigen receptor white blood cells with the goal of addressing major challenges and providing potentially lifesaving treatments for people living with cancer.”3 It is headquartered in South San Francisco, California.1 Its shares trade on Nasdaq under the symbol SNTI.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Allogene Therapeutics, Inc., OPTHEA LIMITED or Enzon Pharmaceuticals, or pick any stock.
- TickerSNTI on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersSouth San Francisco, California1
- Incorporated inDE2
- Business address2 Corporate Drive, First Floor, South San Francisco, Ca 940802
- Filer category, Emerging growth company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches. To accomplish this mission, we have built a synthetic biology platform that we believe may enable us to program next-generation cell and gene therapies with gene circuits. These gene circuits, which we created from novel and proprietary combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments. Using gene circuits, our product candidates are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and cont…3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$37.6M
Out of $22.0K in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration revenue - related party | $22.0K | $0 |
| General and administrative | $26.2M | $26.4M |
| Impairment of long-lived assets | $5.1M | $313.0K |
| Total operating expenses | $68.8M | $61.0M |
| Loss from operations | -$68.8M | -$61.0M |
| Interest income | $927.0K | $948.0K |
| Other income, net | $800.0K | $200.0K |
| Change in fair value of Preferred Stock Tranche Liability - related party | $0 | $13.4M |
| Change in fair value of contingent earnout liability | $0 | $20.0K |
| Total other income, net | $7.3M | $8.2M |
| Net loss | -$61.4M | -$52.8M |
| Comprehensive loss | -$61.4M | -$52.8M |
| Net loss per share, basic (in dollars per share) | -$2.73 | -$12.03 |
| Net loss per share, diluted (in dollars per share) | -$2.73 | -$12.03 |
| Weighted-average shares outstanding, basic (in shares) | 22.5M shares | 4.6M shares |
| Weighted-average shares outstanding, diluted (in shares) | 22.5M shares | 4.6M shares |
| Research and development | $37.6M | $34.4M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $16.4M | $48.3M | ||
| Total current assets | $23.3M | $59.0M | ||
| Restricted cash | $3.5M | $3.5M | ||
| Property and equipment, net | $12.9M | $21.3M | ||
| Operating lease right-of-use assets | $11.5M | $13.9M | ||
| Other non-current assets | $19.0K | $105.0K | ||
| TOTAL ASSETS | $51.2M | $97.8M | ||
| Accounts payable | $2.9M | $1.5M | ||
| Accrued expenses and other current liabilities | $5.4M | $6.4M | ||
| Operating lease liabilities, current | $5.3M | $4.6M | ||
| Deferred revenue, current - related party | $43.0K | $0 | ||
| GeneFab sublease deferred income - related party | $304.0K | $660.0K | ||
| Total current liabilities | $14.0M | $13.1M | ||
| Operating lease liabilities, non-current | $23.6M | $28.9M | ||
| Other non-current liabilities | $8.1M | $5.0M | ||
| TOTAL LIABILITIES | $45.6M | $47.1M | ||
| Series A redeemable convertible preferred stock, $0.0001 par value; zero and 21,200 shares authorized as of December 31, 2025 and 2024, respectively; zero and 21,157 shares issued and outstanding as of December 31, 2025 and 2024, respectively; aggregate liquidation preference of zero and $147,647 as of December 31, 2025 and 2024, respectively | $0 | $25.1M | $0 | |
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of both December 31, 2025 and 2024; 30,879,355 and 4,829,035 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $3.0K | $1.0K | ||
| Additional paid-in capital | $364.2M | $322.8M | ||
| Accumulated deficit | -$358.6M | -$297.1M | ||
| TOTAL STOCKHOLDERS EQUITY | $5.6M | $25.6M | $66.9M | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $51.2M | $97.8M | ||
| Series A redeemable convertible preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Series A redeemable convertible preferred stock, shares authorized (in shares) | 0 shares | 21.2K shares | ||
| Series A redeemable convertible preferred stock, shares issued (in shares) | 0 shares | 21.2K shares | ||
| Series A redeemable convertible preferred stock, shares outstanding (in shares) | 0 shares | 21.2K shares | 0 shares | |
| Series A redeemable convertible preferred stock, liquidation preference | $0 | $147.6M | ||
| Common stock, par or stated value (in dollars per share) | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 30.9M shares | 4.8M shares | ||
| Common stock, shares outstanding (in shares) | 30.9M shares | 4.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $16.4M | $48.3M | ||
| Total current assets | $23.3M | $59.0M | ||
| Restricted cash | $3.5M | $3.5M | ||
| Property and equipment, net | $12.9M | $21.3M | ||
| Operating lease right-of-use assets | $11.5M | $13.9M | ||
| Other non-current assets | $19.0K | $105.0K | ||
| TOTAL ASSETS | $51.2M | $97.8M | ||
| Accounts payable | $2.9M | $1.5M | ||
| Accrued expenses and other current liabilities | $5.4M | $6.4M | ||
| Operating lease liabilities, current | $5.3M | $4.6M | ||
| Deferred revenue, current - related party | $43.0K | $0 | ||
| GeneFab sublease deferred income - related party | $304.0K | $660.0K | ||
| Total current liabilities | $14.0M | $13.1M | ||
| Operating lease liabilities, non-current | $23.6M | $28.9M | ||
| Other non-current liabilities | $8.1M | $5.0M | ||
| TOTAL LIABILITIES | $45.6M | $47.1M | ||
| Series A redeemable convertible preferred stock, $0.0001 par value; zero and 21,200 shares authorized as of December 31, 2025 and 2024, respectively; zero and 21,157 shares issued and outstanding as of December 31, 2025 and 2024, respectively; aggregate liquidation preference of zero and $147,647 as of December 31, 2025 and 2024, respectively | $0 | $25.1M | $0 | |
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of both December 31, 2025 and 2024; 30,879,355 and 4,829,035 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $3.0K | $1.0K | ||
| Additional paid-in capital | $364.2M | $322.8M | ||
| Accumulated deficit | -$358.6M | -$297.1M | ||
| TOTAL STOCKHOLDERS EQUITY | $5.6M | $25.6M | $66.9M | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $51.2M | $97.8M | ||
| Series A redeemable convertible preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Series A redeemable convertible preferred stock, shares authorized (in shares) | 0 shares | 21.2K shares | ||
| Series A redeemable convertible preferred stock, shares issued (in shares) | 0 shares | 21.2K shares | ||
| Series A redeemable convertible preferred stock, shares outstanding (in shares) | 0 shares | 21.2K shares | 0 shares | |
| Series A redeemable convertible preferred stock, liquidation preference | $0 | $147.6M | ||
| Common stock, par or stated value (in dollars per share) | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 30.9M shares | 4.8M shares | ||
| Common stock, shares outstanding (in shares) | 30.9M shares | 4.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$61.4M | -$52.8M |
| Stock-based compensation | $5.7M | $1.8M |
| Depreciation | $3.6M | $3.8M |
| Impairment of long-lived assets | $5.1M | $313.0K |
| Change in fair value of Preferred Stock Tranche liability - related party | $0 | -$13.4M |
| Change in fair value of contingent earnout liability | $0 | -$20.0K |
| Other non-cash charges | $39.0K | $115.0K |
| Operating lease right-of-use assets | $2.3M | $2.0M |
| Accounts payable | $1.7M | $797.0K |
| Accrued expenses and other current liabilities | $559.0K | -$671.0K |
| Operating lease liabilities | -$4.6M | -$4.0M |
| GeneFab sublease deferred income - related party | -$356.0K | -$329.0K |
| Deferred revenue, current - related party | $43.0K | $0 |
| Other non-current liabilities | $0 | $149.0K |
| Net cash used in operating activities | -$43.4M | -$41.4M |
| Purchases of property and equipment | -$196.0K | -$26.0K |
| Proceeds from sale of property and equipment | $12.0K | $60.0K |
| Net cash provided by (used in) investing activities | -$184.0K | $34.0K |
| Proceeds from CIRM Grant | $3.0M | $4.9M |
| Payment of issuance costs | -$2.5M | -$229.0K |
| Proceeds from private placement, net of fees paid to investor | $0 | $47.3M |
| Net cash provided by financing activities | $11.8M | $53.7M |
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | -$31.9M | $12.4M |
| Unpaid Issuance Costs | $34.0K | $1.9M |
No quarter-by-quarter statement was filed.
Compare Senti Biosciences Holdings, Inc. with another company
Corporate structure
Senti Biosciences Holdings, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Senti Biosciences Holdings, Inc.
- Celadon Partners SPV 24 Filed SCHEDULE 13D/A on Senti Biosciences Holdings, Inc., latest Sep 11, 2026 (7 filings since Mar 13, 2025)
- BAYER HEALTHCARE LLC Filed SCHEDULE 13D/A on Senti Biosciences Holdings, Inc., latest Apr 16, 2026 (3 filings since Feb 13, 2023)
- New Enterprise Associates 15, L.P. Filed SCHEDULE 13D/A on Senti Biosciences Holdings, Inc., latest Mar 31, 2026 (4 filings since Jul 15, 2022)
- ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Senti Biosciences Holdings, Inc., latest May 15, 2025 (2 filings since Feb 14, 2025)
- Nantahala Capital Management, LLC Filed SCHEDULE 13G/A on Senti Biosciences Holdings, Inc., latest May 15, 2025 (3 filings since Feb 14, 2025)
- Nantahala Capital Partners Limited Partnership Filed SCHEDULE 13G/A on Senti Biosciences Holdings, Inc., latest May 15, 2025 (2 filings since Feb 14, 2025)
- Joe Lonsdale Filed SCHEDULE 13G/A on Senti Biosciences Holdings, Inc., latest May 7, 2025 (2 filings since Feb 8, 2023)
- PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G on Senti Biosciences Holdings, Inc., latest Feb 14, 2023
- Sculptor Capital LP Filed SC 13G/A on Senti Biosciences Holdings, Inc., latest Feb 14, 2023 (3 filings since Dec 29, 2021)
- Woodline Partners LP Filed SC 13G/A on Senti Biosciences Holdings, Inc., latest Feb 10, 2023 (2 filings since Feb 11, 2022)
- Morgan Stanley Filed SC 13G/A on Senti Biosciences Holdings, Inc., latest Feb 9, 2023 (2 filings since Feb 10, 2022)
- JPMorgan Chase Filed SC 13G/A on Senti Biosciences Holdings, Inc., latest Apr 5, 2022 (2 filings since Feb 3, 2022)
- Senti Biosciences Holdings, Inc. South San Francisco, California
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Senti Biosciences Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $25.9M4 Dec 31, 2025 | $30.8M4 Dec 31, 2024 | −15.9% |
| Accumulated depreciation | $13.1M4 Dec 31, 2025 | $9.6M4 Dec 31, 2024 | +36.7% |
| Property and equipment, net | $12.9M4 Dec 31, 2025 | $21.3M4 Dec 31, 2024 | −39.5% |
| Operating-lease assets (leased space) | $11.5M4 Dec 31, 2025 | $13.9M4 Dec 31, 2024 | −17.4% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $16.4M4 Dec 31, 2025 | $48.3M4 Dec 31, 2024 | −66.0% |
| Debt securities available for sale | $18.2M4 Dec 31, 2025 | $39.4M4 Dec 31, 2024 | −53.8% |
Properties, in its own words
Our corporate headquarters is located in South San Francisco, California, where we lease approximately 40,000 square feet of office and research and development space pursuant to a lease agreement which commenced on April 25, 2019 and expires on April 30, 2027, with an option to extend for eight years. Of the 40,000 square feet, we currently occupy approximately 25,000 square feet of office and research and development space in South San Francisco, CA and entered into a sublease agreement with GeneFab LLC to sublease approximately 7,400 square feet of our office space in South San Francisco expiring April 2027. We also entered into a sublease agreement with BKPBIOTECH, Inc. and JLSA Therapeutics, Inc., to sublease approximately 11,001 square feet of our office space
in South San Francisco commencing October 2024 and also expiring April 2027. In Alameda, California, we leased approximately 92,000 square feet of space as of December 31, 2025 pursuant to a lease agreement that commenced on June 3, 2021 and expires on September 30, 2032, with two options to extend for five years each. In June 2023, we completed the build-out of a cell therapy manufacturing facility designed to meet current Good Manufacturing Practice (“cGMP”) requirements. We subleased the manufacturing space under a sublease agreement to GeneFab that was executed in August 2023 and expires in September 2032. On March 17, 2026, we entered into a First Amendment to Lease and related agreements, pursuant to which the leased premises were reduced to approximately 46,000 square feet. The related sublease with GeneFab was concurrently amended to reflect the reduced premises. We believe that our existing facilities are sufficient to meet our current needs.
Item 2 of the 10-K filed Mar 27, 2026.3
Leadership
Who has led Senti Biosciences Holdings, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerTimothy K. Lu Jun 15, 2022 to now10
- PresidentTimothy K. Lu Jun 15, 2022 to Feb 2, 202410
- Chief financial officerJohn Harry Cross Iii. Mar 11, 2025 to now11
- Chief financial officerYvonne Li May 9, 2024 to May 9, 202412
- Chief financial officerDeborah Knobelman Jun 15, 2022 to Feb 2, 202413
- Chief financial officerMark Afrasiabi May 25, 2021 to May 25, 202114
- Chief operating officerCurt A. Herberts Iii. Jun 15, 2022 to Jun 15, 202215
Board members and other officers (14)
- Chief Technology OfficerPhilip J. Lee Jun 15, 2022 to Feb 2, 202316
- Chief Medical & Devt. OfficerKanya Rajangam Jul 15, 2022 to now17
- Chief Business OfficerRowan E. Chapman May 25, 2021 to May 25, 202118
- Board memberFeng Hsiung Mar 11, 2025 to now19
- Board memberBryan Daniel Baum Jul 21, 2025 to now20
- Board memberFran Schulz Dec 10, 2024 to now21
- Board memberBrenda Cooperstone Jun 15, 2022 to now22
- Board memberEdward T. Mathers Jun 15, 2022 to now23
- Board memberSusan D. Berland Jun 15, 2022 to Jun 21, 202324
- Board memberTimothy K. Lu Jun 15, 2022 to now10
- Board memberDavid R. Epstein May 25, 2021 to Jul 15, 202225
- Board memberDipchand Nishar May 25, 2021 to May 25, 202126
- Board memberJay T. Flatley May 25, 2021 to May 25, 202127
- Board memberOmid Cameron Farokhzad May 25, 2021 to Jul 12, 202428
Named in SEC Form D filings
People the company listed in its private-offering notices.
Former names
Timeline
- Oct 15, 20268-K Shareholder vote30
- Oct 13, 20268-K Other events31
- Sep 24, 20268-K Executive or director change32
- Sep 4, 20268-K Entered a material agreement; New debt or obligation33
- Sep 2, 20268-K Entered a material agreement; Listing notice or transfer34
- Aug 20, 20268-K Entered a material agreement; New debt or obligation35
- Jul 15, 20268-K Entered a material agreement; Results of operations; Change in control36
- May 26, 20268-K Entered a material agreement; New debt or obligation37
- May 14, 20268-K Results of operations; Other events38
- May 1, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares39
- Apr 1, 20268-K Other events40
- Mar 27, 20268-K Results of operations41
- Jun 15, 2022New chief executive Timothy K. Lu becomes CEO10
Calendar
Coming up
- Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.69) a share, on Nov 13, 2025.42
When it reported results
- Jul 15, 2026Reported quarterly or annual results36
- May 14, 2026Reported quarterly or annual results38
- Mar 27, 2026Reported quarterly or annual results41
- Nov 13, 2025Reported quarterly or annual results43
- Aug 7, 2025Reported quarterly or annual results44
- May 6, 2025Reported quarterly or annual results45
- Apr 28, 2025Reported quarterly or annual results46
- Mar 20, 2025Reported quarterly or annual results47
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
333 filings to the SEC since October 2021: 7 annual reports, 17 quarterly reports, 76 major events, 77 insider forms, 36 large holders, 2 private raises, 118 other. The latest 20:
- Oct 15, 20268-K EDGAR
- Oct 13, 2026DEFA14A EDGAR
- Oct 13, 20268-K EDGAR
- Sep 24, 2026EFFECT EDGAR
- Sep 24, 20268-K EDGAR
- Sep 24, 2026424B3 EDGAR
- Sep 24, 2026DEFM14A EDGAR
- Sep 24, 2026PRER14A EDGAR
- Sep 22, 2026S-3/A EDGAR
- Sep 11, 2026SCHEDULE 13D/A EDGAR
- Sep 10, 2026S-3/A EDGAR
- Sep 4, 2026DEFA14A EDGAR
- Sep 4, 20268-K EDGAR
- Sep 4, 2026PRER14A EDGAR
- Sep 2, 2026DEFA14A EDGAR
- Sep 2, 20268-K EDGAR
- Aug 20, 2026DEFA14A EDGAR
- Aug 20, 20268-K EDGAR
- Aug 14, 202610-Q EDGAR
- Jul 21, 2026ARS EDGAR
The 333 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
4 open-market trades by officers, directors and large owners since October 2021: 0 buys and 4 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 6, 2025 | Lu Timothy KCEO | Sale | 545 | $4.36 | $2.4K | Form 4 |
| Feb 6, 2025 | Rajangam KanyaPres. & Chief Med. & Dev. Off. | Sale | 182 | $4.37 | $795 | Form 4 |
| Feb 4, 2025 | Lu Timothy KCEO | Sale | 3,922 | $4.07 | $16.0K | Form 4 |
| Feb 4, 2025 | Rajangam KanyaPres. & Chief Med. & Dev. Off. | Sale | 1,297 | $4.07 | $5.3K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Celadon Partners SPV 24SCHEDULE 13D/A, 7 filings Mar 13, 2025 to Sep 11, 202648
- BAYER HEALTHCARE LLCSCHEDULE 13D/A, 3 filings Feb 13, 2023 to Apr 16, 202649
- New Enterprise Associates 15, L.P.SCHEDULE 13D/A, 4 filings Jul 15, 2022 to Mar 31, 202650
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 2 filings Feb 14, 2025 to May 15, 202551
- Nantahala Capital Management, LLCSCHEDULE 13G/A, 3 filings Feb 14, 2025 to May 15, 202552
- Nantahala Capital Partners Limited PartnershipSCHEDULE 13G/A, 2 filings Feb 14, 2025 to May 15, 202553
- Joe LonsdaleSCHEDULE 13G/A, 2 filings Feb 8, 2023 to May 7, 202554
- PRICE T ROWE ASSOCIATES INC /MD/SC 13G, 1 filing Feb 14, 202355
- Sculptor Capital LPSC 13G/A, 3 filings Dec 29, 2021 to Feb 14, 202356
- Woodline Partners LPSC 13G/A, 2 filings Feb 11, 2022 to Feb 10, 202357
- Morgan StanleySC 13G/A, 2 filings Feb 10, 2022 to Feb 9, 202358
- JPMorgan ChaseSC 13G/A, 2 filings Feb 3, 2022 to Apr 5, 202259
- Redmile Group, LLCSC 13G/A, 1 filing Feb 14, 202260
- ARK Investment Management LLCSC 13G/A, 2 filings Feb 9, 2022 to Feb 10, 202261
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2024 | Timothy LuM.D., Ph.D. | $618.8K | $930.7K62 | |
| 2024 | Kanya RajangamM.D., Ph.D. | $526.8K | $858.8K62 | |
| 2024 | Yvonne Li | $547.5K62 | ||
| 2023 | Chief Executive Officer | $606.6K | $1.7M62 | |
| 2023 | PresidentHead of Research and Development and Chief Medical Officer | $516.5K | $627.7K62 |
Money raised
Private offerings the company reported to the SEC on Form D.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 888,000 | $976.8K | 0.0% | New |
| Vanguard Capital Management LLC | 537,504 | $591.3K | 0.0% | New |
| Geode Capital Management, LLC | 187,065 | $205.8K | 0.0% | New |
| Citadel Advisors LLC | 107,100 | $117.8K | 0.0% | New |
| Vanguard Fiduciary Trust Co | 91,193 | $100.3K | 0.0% | New |
| Jane Street Group, LLC | 52,530 | $57.8K | 0.0% | New |
| Menlo Ventures Management, L.P. | 35,737 | $39.3K | 0.0% | New |
| Northern Trust Corp | 32,154 | $35.4K | 0.0% | New |
| XTX Topco Ltd | 23,610 | $26.0K | 0.0% | New |
| UBS Group AG | 14,432 | $15.9K | 0.0% | New |
| Tower Research Capital LLC (TRC) | 7,344 | $8.1K | 0.0% | New |
| BlackRock, Inc. | 4,004 | $4.4K | 0.0% | New |
| Royal Bank Of Canada | 4,015 | $4.0K | 0.0% | New |
| Barclays PLC | 768 | $845 | 0.0% | New |
| SBI Securities Co., Ltd. | 334 | $367 | 0.0% | New |
| Morgan Stanley | 169 | $186 | 0.0% | New |
| Virtu Financial LLC | 22,795 | $25 | 0.0% | New |
| Caitong International Asset Management Co., Ltd | 1 | $1 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Senti Biosciences Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARSenti Biosciences Holdings, Inc.1
- CIK0001854270
- Employer ID (EIN)86-24379003
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inDelaware3
- Fiscal year endsDecember 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address2 Corporate Drive, First Floor, South San Francisco, CA 940801
- Phone(650) 239-20301
- Shares outstanding31,144,754 as of Jul 31, 20269
- Public float$53.2M as of Jun 30, 20253
- AuditorKPMG LLP, San Francisco, CA, PCAOB ID 185; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceApr 2, 20211
- Filings363 in all: 8-K (76), 4 (57), 424B3 (28), 3 (27), 10-Q (17), CORRESP (13), EFFECT (13), SC 13G (10)1
All 47 form types
SC 13G/A (9), SCHEDULE 13D/A (9), DEFA14A (8), UPLOAD (8), 425 (6), POS AM (6), 10-K (5), S-8 (5), SCHEDULE 13G/A (5), ARS (4), DEF 14A (4), S-8 POS (4), 424B5 (3), S-1 (3), S-1/A (3), S-3 (3), S-3/A (3), S-4/A (3), SCHEDULE 13G (3), 10-K/A (2), 10-Q/A (2), D (2), DEFM14A (2), PRE 14A (2), PRER14A (2), SCHEDULE 13D (2), SEC STAFF LETTER (2), 144 (1), 15-12G (1), 4/A (1), 8-A12B (1), 8-K/A (1), 8-K12B (1), CERT (1), DRS (1), PREM14A (1), S-4 (1), SC 13D (1), SC 13D/A (1)
- Latest filingsAnnual report (10-K) Mar 27, 2026
Quarterly report (10-Q) Aug 14, 2026
Proxy statement (DEF 14A) Apr 30, 2025
Latest 8-K (8-K) Oct 15, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common stock, par value $0.0001 per share | SNTI | Nasdaq |
From the cover page of the 10-K filed Mar 27, 2026 (Section 12(b) of the Exchange Act).3
Risk factors and legal proceedings
The risks Senti Biosciences Holdings, Inc. names in Item 1A of its 10-K filed Mar 27, 2026: 73 risks under these headings, as written.3
- Risks Related to Our Limited Operating History and Financial Condition
- We are an early stage clinical biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.
- We will need substantial additional funding, and there is substantial doubt about our ability to continue as a going concern. If we are unable to raise capital when needed on acceptable terms, or at all, we may be forced to
- restructure our business or delay, reduce, or terminate our research and product development programs, future commercialization efforts or other operations.
- Our streamlining of business operations, including workforce reduction and re-prioritization plan announced in January 2024, may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.
- We previously identified a material weakness in our internal control over financial reporting. If we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of shares of our common stock.
- Members of our management team have limited experience in managing the day-to-day operations of a public company and, as a result, we may incur additional expenses associated with the management of our company.
- Our ability to use net operating loss carryforwards (“NOLs”) and credits to offset future taxable income may be subject to certain limitations.
- The U.S. Congress, the current U.S. presidential administration, or any subsequent administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business.
- The sale or issuance of our common stock to Celadon Partners may cause significant dilution and the sale of the shares of common stock acquired by Celadon Partners, or the perception that such sales may occur, could cause the price of our common stock to fall.
- Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.
- Risks Related to the Development and Clinical Testing of Our Product Candidates
The other 63 risks
- Our current product candidates are in early clinical or preclinical development. One or all of our current product candidates may fail in clinical development or suffer delays that materially and adversely affect their commercial viability.
- Clinical trials of our current or potential future product candidates may not demonstrate the safety, purity and potency, or efficacy, necessary for such product candidates to become approvable or commercially viable.
- Our gene circuit platform technologies are based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval.
- The occurrence of serious complications or side effects in connection with the use of our product candidates, either in clinical trials or post-approval, could lead to discontinuation of our clinical development programs, refusal of regulatory authorities to approve our product candidates, or, post-approval, revocation of marketing authorizations or refusal to approve applications for new indications, which could severely harm our business, prospects, operating results, and financial condition.
- We may not be successful in our efforts to use and expand our gene circuit platform to grow our pipeline of product candidates.
- Although we intend to explore other therapeutic opportunities in addition to the product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed.
- The market, physicians, patients, regulators and potential investors may not be receptive to our current or potential future product candidates and may be skeptical of the viability and benefits of our gene circuit pipeline technology because it is based on a relatively novel and complex technology.
- We may not be able to file additional INDs to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.
- Interim, topline and preliminary data that we announce or publish from time to time for any clinical trials that we initiate may change as more patient data become available or as additional analyses are conducted, and as the data are subject to audit and verification procedures that could result in material changes in the final data.
- We and our collaborators may not achieve projected discovery and development milestones and other anticipated key events in the time frames that we or they announce, which could have an adverse impact on our business and could cause our stock price to decline.
- Clinical trials are expensive, time-consuming and difficult to design and implement.
- If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
- If clinical trials for our product candidates are prolonged, delayed or stopped, we may be unable to seek or obtain regulatory approval and commercialize our product candidates on a timely basis, or at all, which would require us to incur additional costs and delay our receipt of any product revenue.
- Despite receiving orphan drug designation for SENTI-202 for one indication, if we decide to seek orphan drug designation for one or more of our other product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation for our current or future product candidates that we may develop.
- We may not be able to conduct, or contract with others to conduct, animal testing in the future, which could harm our research and development activities.
- Risks Related to Our Reliance on Third Parties
- There can be no assurance that we will achieve all of the anticipated benefits of the transactions with GeneFab and we could face unanticipated challenges.
- We currently rely and intend to continue to rely on third parties to conduct our clinical trials and preclinical studies, and those third parties may not perform satisfactorily.
- In the past, we have depended on strategic partnerships and collaboration arrangements, such as our collaboration arrangements with BlueRock Therapeutics, Inc., or BlueRock, and Celest Therapeutics, for the application of our gene circuit platform technology to the development and commercialization of potential product candidates in certain indications, and if these arrangements are unsuccessful, this could impair our ability to generate revenues and harm our results of operations.
- We may not be able to enter into additional strategic transactions on acceptable terms, if at all, which could adversely affect our ability to develop and commercialize current and potential future product candidates and technologies, impact our cash position, increase our expenses and present significant distractions to our management.
- Risks Related to Manufacturing
- Manufacturing our current or future product candidates is complex and the third parties upon whom we rely to provide manufacturing services may encounter difficulties in production. If we encounter such difficulties, our ability to provide supply of our current or future product candidates for preclinical studies and clinical trials or, if approved, for commercial sale, for commercial purposes could be delayed or halted entirely.
- Supply of our product candidates for preclinical and clinical development may become limited or interrupted or may not be of satisfactory quantity or quality, and we may experience delays if GeneFab is unable to consistently and reliably manufacture any current and future products and we are required to rely on third-party back-up manufacturers.
- GeneFab or any other third-party manufacturers that we use may be unable to successfully scale the manufacturing of our current or potential future product candidates in sufficient quality and quantity, which would delay or prevent us from developing our current and potential future product candidates and commercializing approved products candidates, if any. GeneFab has never operated a cGMP facility before.
- We are exposed to a number of risks related to our supply chain for the materials required to manufacture our product candidates.
- Changes in methods of product candidate manufacturing or formulation may result in the need to perform new clinical trials, which would require additional costs and cause delay.
- Risks Related to Our Business and Operations
- If the market opportunities for our current and potential future product candidates, including SENTI-202, are smaller than we believe they are, our future product revenues may be adversely affected, and our business may suffer.
- We face competition from companies that have developed or may develop product candidates for the treatment of the diseases that we may target, including companies developing novel therapies and platform technologies. If these companies develop platform technologies or product candidates more rapidly than we do, or if their platform technologies or product candidates are more effective, have fewer side effects, or less expensive our ability to develop and successfully commercialize product candidates may be adversely affected.
- Any inability to attract and retain qualified key management, technical personnel and employees would impair our ability to implement our business plan.
- We may experience difficulties in managing our growth and expanding our operations.
- If any of our product candidates is approved for marketing and commercialization in the future and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future products.
- Our commercial relationships with entities outside of the United States and our potential future international operations may expose us to business, political, operational and financial risks associated with doing business outside of the United States.
- Our business entails a significant risk of product liability, and our inability to obtain sufficient insurance coverage could have a material adverse effect on our business, financial condition, results of operations and prospects.
- Our employees, principal investigators, consultants and commercial collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
- We depend on sophisticated information technology systems and data processing to operate our business. If we experience cybersecurity or data privacy breaches, security incidents or compromises, or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, we may face costs, significant liabilities, harm to our brand and business disruption.
- If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
- Unfavorable global economic conditions and government regulations could adversely affect our business, financial condition or results of operations.
- Terrorist attacks, natural disasters, public health crises, political unrest or other catastrophic events outside of our control may adversely affect our business.
- Market volatility and economic downturns may harm our business and results of operations and negatively affect our stock price.
- Recent volatility in capital markets and lower market prices for our securities may affect our ability to access new capital through sales of shares of our common stock or issuance of indebtedness, which may harm our liquidity, limit our ability to grow our business, pursue acquisitions or improve our operating infrastructure and restrict our ability to compete in our markets.
- Rising inflation rates could negatively impact our business. If our costs increase, our net losses would increase, which may have a material adverse effect on our business.
- Risks Related to Our Intellectual Property
- If we are unable to obtain or protect intellectual property rights related to our technology and current or future product candidates, or if our intellectual property rights are inadequate, our competitors could develop and commercialize products and technology similar or identical to ours, and we may not be able to compete effectively in our market or successfully commercialize any product candidates we may develop.
- The patent protection and patent prosecution for some of our product candidates and technologies may be dependent on third parties.
- We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations.
- We currently, and in the future may continue to, enter into agreements involving licenses or collaborations that provide for access or sharing of intellectual property. These intellectual property-related agreements may impose certain obligations and restrictions on our ability to develop and commercialize our product candidates and technologies that are the subject of such licenses.
- If we fail to comply with our obligations or disputes arise under any existing or future license, collaboration or other intellectual property-related agreements, we may be required to pay damages and could lose intellectual property rights that may be necessary for developing, commercializing and protecting our current or future technologies or product candidates or we could lose certain rights to grant sublicenses.
- Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or product candidates.
- Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current or any future technologies or product candidates.
- We may be subject to lawsuits or litigation to protect or enforce our patents or other intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products.
- We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.
- Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse impact on the success of our business.
- Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our shares of our common stock to decline.
- Intellectual property rights of third parties could adversely affect our ability to commercialize our current or future technologies or product candidates, and we might be required to litigate or obtain licenses from third parties to develop or market our current or future technologies or product candidates, which may not be available on commercially reasonable terms or at all.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
- We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets or other proprietary information of third parties, including our employees’ or consultants’ former employers or their clients.
- We may be subject to claims challenging the inventorship of our patents and other intellectual property.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
- Intellectual property rights do not necessarily address all potential threats to our business.
- Risks Related to Government Regulation
- Clinical development includes a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
- We may be unable to obtain U.S. or foreign regulatory approval and, as a result, be unable to commercialize our current or potential future product candidates.
- Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
- We may conduct certain of our clinical trials for our product candidates outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.
- Even if we receive regulatory approval for any of our current or potential future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our current or potential future product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.
- Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.
Legal proceedings
From time to time we may become involved in legal proceedings to claims arising in the ordinary course of our business. We are not currently a party to any such material legal proceedings.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARYvonne Li, Chief financial officer
- 13
- 14
- 15
- 16
- 17
- 18
- 19SEC EDGARFeng Hsiung, Board member
- 20SEC EDGARBryan Daniel Baum, Board member
- 21SEC EDGARFran Schulz, Board member
- 22SEC EDGARBrenda Cooperstone, Board member
- 23SEC EDGAREdward T. Mathers, Board member
- 24SEC EDGARSusan D. Berland, Board member
- 25SEC EDGARDavid R. Epstein, Board member
- 26SEC EDGARDipchand Nishar, Board member
- 27SEC EDGARJay T. Flatley, Board member
- 28SEC EDGAROmid Cameron Farokhzad, Board member
- 29
- 30SEC EDGARShareholder vote
- 31SEC EDGAROther events
- 32SEC EDGARExecutive or director change
- 33
- 34
- 35
- 36
- 37
- 38SEC EDGARResults of operations; Other events
- 39
- 40SEC EDGAROther events
- 41SEC EDGARResults of operations
- 42NasdaqNasdaq calendar
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62